{"doi":"10.3389/fcell.2022.942500","title":"Recent advances in targeting protein kinases and pseudokinases in cancer biology","abstract":"<jats:p>Kinases still remain the most favorable members of the druggable genome, and there are an increasing number of kinase inhibitors approved by the FDA to treat a variety of cancers. Here, we summarize recent developments in targeting kinases and pseudokinases with some examples. Targeting the cell cycle machinery garnered significant clinical success, however, a large section of the kinome remains understudied. We also review recent developments in the understanding of pseudokinases and discuss approaches on how to effectively target in cancer.</jats:p>","journal":"Frontiers in Cell and Developmental Biology","year":2022,"id":595182,"datarank":0.4887144807032224,"base_score":3.258096538021482,"endowment":3.258096538021482,"self_citation_contribution":0.4887144807032224,"citation_network_contribution":0.0,"self_endowment_contribution":0.4887144807032224,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":25,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":118059,"name":"Parthiban Vijayarangakannan","orcid":null,"position":1,"is_corresponding":false},{"id":1523958,"name":"Petros Kechagioglou","orcid":null,"position":2,"is_corresponding":false},{"id":1523961,"name":"Katarzyna Bogucka","orcid":null,"position":3,"is_corresponding":false},{"id":1523964,"name":"Krishnaraj Rajalingam","orcid":null,"position":4,"is_corresponding":false},{"id":1523954,"name":"Kristina Riegel","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Recent advances in targeting protein kinases and pseudokinases in cancer biology","abstract":"<jats:p>Kinases still remain the most favorable members of the druggable genome, and there are an increasing number of kinase inhibitors approved by the FDA to treat a variety of cancers. Here, we summarize recent developments in targeting kinases and pseudokinases with some examples. Targeting the cell cycle machinery garnered significant clinical success, however, a large section of the kinome remains understudied. We also review recent developments in the understanding of pseudokinases and discuss approaches on how to effectively target in cancer.</jats:p>","is_dataset_classified":null,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35938171","pmcid":"PMC9354965","openalex_id":"https://openalex.org/W4286488808","authors":[],"funders":[],"total_grants":0,"fwci":1.6453,"citation_percentile":0.83985102,"influential_citations":0,"citation_trend":[{"year":2023,"count":3},{"year":2024,"count":10},{"year":2025,"count":8},{"year":2026,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.frontiersin.org/articles/10.3389/fcell.2022.942500/pdf","host_type":"journal"},{"url":"https://www.frontiersin.org/articles/10.3389/fcell.2022.942500/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fcell.2022.942500/full","host_type":"publisher"},{"url":"https://doi.org/10.3389/fcell.2022.942500","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35938171","host_type":"repository"},{"url":"https://doaj.org/article/3f5f52a6d10b4ee3b28a495b508e6a22","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9354965","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9354965","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9354965?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Protein Degradation and Inhibitors","Cancer-related Molecular Pathways","Microtubule and mitosis dynamics"],"mesh_terms":[],"keywords":["Kinome","Druggability","Kinase","Protein-Serine-Threonine Kinases","Biology","Computational biology","Bioinformatics","Protein kinase A","Cell biology","Gene","Genetics","Inhibitors","Cancer","MAPK","Allosteric regulation","Raf","Molecular Switch","Cdk4/6"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"gen"},{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T16:49:50.099230Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}